Erratum to: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
© Nielsen et al; licensee BioMed Central Ltd. 2011
Received: 4 February 2011
Accepted: 4 February 2011
Published: 4 February 2011
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
In our article , we did not declare some potential competing interests for Prof. Dr. med. Ludwig Kappos:
Declaration of competing interests:
Prof. Dr. med. Ludwig Kappos
LK has participated in the last 24 months as principal investigator, member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. The sponsoring pharmaceutical companies for these trials include Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, GeNeuro SA, Genmark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novonordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB and Wyeth.
I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies.
Honoraria and other payments for all these activities have been exclusively used for funding of research of my department.
Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto, Novartis and Roche Research Foundations.
- Nielsen Jessica, Pohl Christoph, Polman Chris, Barkhof Frederik, Freedman Mark, Edan Gilles, Miller David, Bauer Lars, Sandbrink Rupert, Kappos Ludwig, Uitdehaag Bernard: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. BMC Neurology. 2009, 9: 19-10.1186/1471-2377-9-19.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/19/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.